FOLH1 and chronic kidney disease: While there has been concern about renal toxicity, a recent study of metastatic CRPC patients with at least CKD stage 3 showed that RLT (at least 2 cycles of 177Lu-PSMA-617; median 5 cycles) led to stable or improved GFR in most patients (71).